CN Patent

CN115956080B — 双环化合物，包含其的组合物及其应用

Assigned to Betta Pharmaceuticals Co Ltd · Expires 2025-07-11 · 1y expired

What this patent protects

提供了式(I)所示化合物，包含其的药用组合物和其应用。所述化合物可用于治疗，预防或改善诸如癌症之类的疾病或障碍。

USPTO Abstract

提供了式(I)所示化合物，包含其的药用组合物和其应用。所述化合物可用于治疗，预防或改善诸如癌症之类的疾病或障碍。

Drugs covered by this patent

Krazati (ADAGRASIB) · Bristol-Myers Squibb

Patent Metadata

Patent number: CN115956080B
Jurisdiction: CN
Classification: —
Expires: 2025-07-11
Drug substance claim: No
Drug product claim: No
Assignee: Betta Pharmaceuticals Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.